Similar companies
| Company | Transaction Value | |
|---|---|---|
 |
OcugenOCGN |
-$10M |
 |
Gilead SciencesGILD |
-$4.04B |
 |
AmgenAMGN |
-$189M |
 |
Editas MedicineEDIT |
-$7M |
 |
Crispr TherapeuticsCRSP |
-$163M |
Are Conduit Pharmaceuticals Insiders Buying or Selling?
Conduit Pharmaceuticals (CDT) has had 1 insider transaction in the past 90 days, all sells. The most recent was Andrew Regan, who sold 290 shares at $0.00 on August 28, 2026.
Insider trading patterns can signal confidence or concern from the people who know the company best. AltIndex tracks insider transactions as one of 25+ alternative data signals in the CDT AI Score. For government officials trading this stock, see CDT congressional trading.
Who’s Trading Conduit Pharmaceuticals Stock?
| Insider | Activity | Trades | Last Trade |
|---|---|---|---|
| Taylor Mark Andrew | Sold $2.9M | 3 | Jun 18, 2026 |
| Andrew Regan | Mixed $0 | 1 | Aug 28, 2026 |
Recent Conduit Pharmaceuticals Insider Transactions
| Insider | Transaction Date | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| Andrew Regan | Aug 28, 2026 | Sell | 290 | $0 | $0 |
| Taylor Mark Andrew | Jun 18, 2026 | Sell | 1,464,711 | $1.44 | $2.1M |
| Taylor Mark Andrew | Jun 18, 2026 | Sell | 593,289 | $1.4 | $830,000 |
| Taylor Mark Andrew | Jun 18, 2026 | Sell | 5,000 | $0.75 | $3,800 |
Frequently Asked Questions: Conduit Pharmaceuticals Insider Trading
In the past 90 days, Conduit Pharmaceuticals insiders have made 0 buys and 1 sell. The net selling may indicate insiders are taking profits or reducing exposure.
The most recent sale was by Andrew Regan who sold 290 shares on August 28, 2026. View all transactions in the table on this page.
Insider buying is generally a stronger signal than insider selling, since insiders may sell for personal reasons (diversification, taxes) but typically buy only when they believe the stock is undervalued. AltIndex uses insider transaction patterns alongside 25+ other signals in the AI Score.
Taylor Mark Andrew has sold the most CDT stock in the last 2 years, with a total value of $2.9M.
The total value of insider transactions for Conduit Pharmaceuticals in the last 2 years is negative, amounting to -$2.9M. This suggests that insiders have predominantly sold shares, which could reflect various personal or financial considerations rather than a straightforward outlook on the company's future performance.
